StockData
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. (ORMP) company profile

ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.71−0.32 (-7.94%)

Close on Nov 13, 2026Market cap $154.33MP/E 1.1Yield 6.74%

About Oramed Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Oramed Pharmaceuticals Inc. is a pharmaceutical company that researches and develops oral delivery solutions for therapeutic proteins. Its proprietary Protein Oral Delivery technology enables oral formulations designed to protect active proteins, such as insulin, from gastrointestinal degradation and allow safe oral absorption without biological or chemical modification. In addition to internal development activities, the company allocates capital to strategic investments, royalty arrangements, and partnerships across healthcare, biotechnology, and life sciences businesses.

The company maintains its principal executive offices in New York, New York, and operates a wholly-owned subsidiary, Oramed Ltd. Its operational presence and business activities involve partnerships, clinical trial programs, and corporate agreements across the United States, Israel, and the British Virgin Islands.

Summary of the business section of Oramed Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Oramed Pharmaceuticals Inc.
Founded
2002
Headquarters
New York, NY
Address
1185 Avenue Of The Americas, 3rd Floor 10036
Phone
(646) 844-1164
Employees
13, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Kesselman & Kesselman C.P.A.s, Tel Aviv, Israel

Stock & identifiers

Ticker
ORMP
Exchange
Nasdaq
Shares outstanding
42M, Aug 10, 2026
Public float
$77.66M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-12 reverse, Jan 23, 2013
SEC CIK
1176309
CUSIP
68403P203
ISIN
US68403P2039
FIGI
BBG000LRYR36
Share class FIGI
BBG001SK4M90
LEI
5299006K52ZIIGQJ6R84
EIN
98-0376008

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Miriam KidronChief Scientific Officer, Director2,149,554
Nadav KidronPresident and CEO, Director5,583,505
Joshua HexterCOO & CBO1,927,130
Avraham GabayChief Financial Officer1,460,076
Yehuda ReznickDirector180,850
Arie MayerDirector242,259
Benjamin ShapiroDirector2,097,050
Daniel AghionDirector189,111
Leonard SankDirector273,420

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.77M$4.80M$2.02M$118–
FY2024$2.10M$2.14M$1.28M$105–
FY2023$1.66M$265.81K$918.94K$19–
FY2022$6.83M$7.45M$2.17M$84–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOtherTotalvs. prior year
Nadav Kidron
President, Chief Executive Officer and Chairman
$619.53K$379.94K$3.71M$65.93K$4.77M+128%
Dr. Miriam Kidron
Chief Scientific Officer and director
$439.90K$271.99K$1.41M$48.46K$2.17M+41%
Joshua Hexter
Chief Operating and Business Officer
$285.43K$218.15K$1.30M$79.75K$1.88M+83%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we have contracted with thirteen individuals for employment or consulting arrangements.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 15, 2026Late filingNotification of late filing
Mar 31, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 17, 2025ListingRegistration of securities on an exchange (Form 8-A)
Jul 16, 2013Late filingNotification of late filing
Feb 7, 2013ListingRegistration of securities on an exchange (Form 8-A)
Nov 29, 2012Late filingNotification of late filing
Apr 6, 2011Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 16, 2008Late filingNotification of late filing
Apr 4, 2008Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 29, 2007Late filingNotification of late filing
Jul 17, 2007Late filingNotification of late filing
Apr 16, 2007Late filingNotification of late filing
Jan 16, 2007Late filingNotification of late filing
Nov 29, 2006Late filingNotification of late filing
Apr 10, 2006Name changeName changed from Integrated Security Technologies, Inc. to Oramed Pharmaceuticals Inc.
Mar 13, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 16, 2005Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 28, 2004Late filingNotification of late filing
Jun 10, 2004Name changeName changed from IGUANA VENTURES LTD to Integrated Security Technologies, Inc.
Apr 15, 2004Late filingNotification of late filing
Jan 15, 2004Late filingNotification of late filing

See a number that looks wrong?